Media Articles Related to Protriptyline
Activating neurons that trigger depression could help treat it, study suggests
Source: Anxiety / Stress News From Medical News Today [2014.04.19]
Researchers from the Icahn School of Medicine at Mount Sinai found that activating neurons linked to stress-induced depression may actually increase resilience to the condition.
Stroke Rounds: Depression Tied to Worse Stroke Outcomes (CME/CE)
Source: MedPage Today Cardiovascular [2014.04.17]
(MedPage Today) -- Depression was found to be a significant and independent risk factor for poor stroke outcomes in a study from the U.K., and recovery from depression within a year did not alter long-term risk.
Symptoms of depression surge in young men during early fatherhood
Source: Depression News From Medical News Today [2014.04.16]
Depression can hit young fathers hard -- with symptoms increasing dramatically during some of the most important years of their children's lives, a new Northwestern MedicineR study has found.
Study: When depression does not respond to treatment
Source: Complementary Medicine / Alternative Medicine News From Medical News Today [2014.04.15]
Notwithstanding numerous advances in the pharmacological treatment of depression, approximately 70% of patients do not remit after first-line antidepressant treatment.
Preschool Depression Strong Predictor of Later MDD
Source: Medscape Psychiatry & Mental Health Headlines [2014.04.14]
Preschoolers with depressive syndrome run a significantly increased risk for major depression later in childhood.
Medscape Medical News
Published Studies Related to Protriptyline
Effect of protriptyline, 10 mg daily, on chronic hypoxaemia in chronic obstructive pulmonary disease. [1995.03]
A daily dose of 20 mg of protriptyline can improve daytime arterial blood gas tensions in chronic obstructive pulmonary disease (COPD)... Despite the low dose, anticholinergic side-effects occurred in most patients.
The use of protriptyline for respiratory failure in patients with chronic airflow limitation. [1990.07]
Treatment of nocturnal hypoventilation in patients with restrictive chest wall disease and respiratory failure, results in improved daytime arterial blood gas tensions, increase in functional ability and longer survival. Success has been achieved with the use of protriptyline which reduces the duration of rapid eye movement (REM) sleep during which nocturnal hypoventilation occurs.
Effect of protriptyline on ventilatory responses to hypercapnia and asphyxia in normal subjects. [1989.09]
A double-blind crossover study was undertaken to assess the effect of protriptyline on ventilatory responses in normal subjects. Seven subjects received in random order placebo, 10 mg and 20 mg protriptyline daily for 2 weeks... Mean HCVR and HVR following 10 mg and 20 mg protriptyline did not differ significantly from measurements on placebo, neither for the single dose study or after 2 weeks.
Role of protriptyline and acetazolamide in the sleep apnea/hypopnea syndrome. [1988.10]
The role of drug therapy in the treatment of the sleep apnea/hypopnea syndrome is unclear. In a randomised, double-blind, placebo-controlled study, we investigated the value of 14-day therapy with protriptyline (20 mg daily) or acetazolamide (250 mg 4 times per day) on symptoms and on the frequency of apneas, hypopneas, arousals, and 4% desaturations in 10 patients with obstructive sleep apnea/hypopnea syndrome.
Clinical Trials Related to Protriptyline
Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism [Recruiting]
Reduction of volume of the hippocampus has been associated with major depression in many
studies. It has been suggested that antidepressants may protect against hippocampus volume
loss in humans associated with multiple episodes of depression and may also reverse the
reduction of volume caused by the depression. In addition, genetic markers for serotonin are
implicated with depression, and may be an indication of reduced response to antidepressant
This study aims to enroll patients who are defined as having treatment resistant depression
(no remission after at least 2 treatments trials with an antidepressant). They will receive
an MRI scan at the initial visit and either 6 months after sustained remission or 12 months
after they enter the study for non-remitters. They will also be asked to give a blood sample
for genotyping. They will be matched by age and handedness to healthy volunteers with no
personal history of depression who will also receive an MRI scan and genotyping.
The first aim is to compare hippocampal volume of depressed subjects to healthy controls. It
is anticipated that subjects will initially have smaller hippocampal volume but of those who
sustain remission, there will be a small increase in hippocampal volume. It is also
anticipated that specific genetic markers will be related to individuals response to